Business
BioSpectrum Asia
Poly Medicure announces acquisition of Citieffe Group for Rs 324 Cr
India-based medtech firm Poly Medicure has announced signing of a definitive agreement to acquire 100 per cent stake in Medistream SA (Group) consisting of Citieffe SRL and its step-down subsidiaries in USA & Mexico, at an Enterprise Value of Rs 324 crore (EUR 31 million).
1 min |
BioSpectrum Asia Nov 2025
BioSpectrum Asia
Sumitomo, Novo Nordisk to co-promote obesity drug Wegovy in Japan
Sumitomo Pharma and Novo Nordisk Pharma have entered into a co-promotion agreement in Japan for Wegovy Subcutaneous Injection, a once-weekly subcutaneous injection formulation of GLP-1 receptor agonist indicated for the treatment of obesity disease.
1 min |
BioSpectrum Asia Nov 2025
BioSpectrum Asia
Cell Therapies partners with Teijin to expand access to advanced CGT in APAC
Australia-based Cell Therapies and Japan's Teijin have signed a Memorandum of Understanding (MoU) to strengthen regional infrastructure for cell and gene therapies (CGT), leveraging advanced GMP capabilities and cross-border collaboration to accelerate development and improve patient access across Japan and the wider Asia Pacific (APAC) region.
1 min |
BioSpectrum Asia Nov 2025
BioSpectrum Asia
Singapore boosts medtech regulatory support and market access
The Health Sciences Authority (HSA) and the Singapore Manufacturing Federation Medical Technology Industry Group (SMF MTIG) are pioneering a comprehensive support ecosystem for Singapore's MedTech industry through their strategic partnership, combining the SME Centre@SMF's services with HSA's Health Products Regulation Group (HPRG) Innovation Office's technical regulatory expertise.
1 min |
BioSpectrum Asia Nov 2025
BioSpectrum Asia
US FDA authorises marketing of first eyeglass lenses to slow progression of paediatric myopia
The US Food and Drug Administration (FDA) has authorised marketing of the Essilor Stellest eyeglass lenses to correct myopia, commonly referred to as nearsightedness, with or without astigmatism and to slow the progression of the disease in children 6 to 12 years old at the initiation of treatment.
1 min |
BioSpectrum Asia Nov 2025
BioSpectrum Asia
Korea designs bioadhesive sponge offering new way to stop internal bleeding
Uncontrolled bleeding during surgery remains one of the deadliest medical emergencies.
1 min |
BioSpectrum Asia Nov 2025
BioSpectrum Asia
K-Bio Lab Hub inks MoU with Australia's Monash University
Australia’s biotech capital, Melbourne, has further strengthened its research and development capabilities through a newly formed Memorandum of Understanding (MoU) between Monash University and K-Bio Lab Hub — South Korea’s government-backed biotech incubator.
1 min |
BioSpectrum Asia Nov 2025
BioSpectrum Asia
Clinical trial by Australia marks key milestone in fight against antibiotic resistance
An international clinical trial, led by The University of Queensland (UQ) in Australia, has been hailed as a significant step forward in the global challenge of antibiotic resistance.
1 min |
BioSpectrum Asia Nov 2025
BioSpectrum Asia
WHO to advance digitised health systems in sub-Saharan Africa
The World Health Organization (WHO) and the European Union (EU) have announced a new agreement to support the digital transformation of health systems and wider adoption of WHO's Global Digital Health Certification Network (GDHCN) in sub-Saharan Africa.
1 min |
BioSpectrum Asia Nov 2025
BioSpectrum Asia
Indian PM approves DSIR Scheme of Capacity Building and HR Development with outlay of Rs 2277 Cr
The Cabinet, chaired by the Prime Minister Narendra Modi, has approved the Department of Scientific and Industrial Research / Council of Scientific and Industrial Research (DSIR/CSIR) Scheme on “Capacity Building and Human Resource (HR) Development” with a total outlay of Rs 2277.397 crore for the period of the Fifteenth Finance Commission Cycle 2021-22 to 2025-26.
1 min |
BioSpectrum Asia Nov 2025
BioSpectrum Asia
Nanyang Biologics plans NASDAQ listing through $1.5 B biz combination
Singapore-based startup Nanyang Biologics (NYB) has entered into a business combination agreement (BCA) with RF Acquisition Corp II (RFAI), a publicly traded special purpose acquisition company, in a transaction aimed at making NYB become a publicly listed company.
1 min |
BioSpectrum Asia Nov 2025
BioSpectrum Asia
Japan generates iPS cells from human peripheral blood cells
A team of scientists at Kyoto University, Japan has successfully established induced pluripotent stem (iPS) cells from peripheral blood mononuclear cells (PBMCs) using synthetic RNA, which has been a technical challenge until now.
1 min |
BioSpectrum Asia Nov 2025
BioSpectrum Asia
Serum Institute of India & CEPI supercharge pandemic response preparedness targeting H5N1
Norway-based Coalition for Epidemic Preparedness Innovations (CEPI) is collaborating with Pune-based Serum Institute of India (SII), part of Cyrus Poonawalla Group, to boost pandemic response preparedness using a baculovirus vaccine platform to target H5N1 bird flu as a prototype for a potential Disease X—an as-yet-unknown pathogen with pandemic potential.
1 min |
BioSpectrum Asia Nov 2025
BioSpectrum Asia
Africa to strengthen public health workforce capacity for NCD surveillance
The Africa Centres for Disease Control and Prevention (Africa CDC) has partnered with the Novo Nordisk Foundation, a Danish enterprise Foundation, to strengthen public health workforce capacity for Non-Communicable Disease (NCD) surveillance across ten African Union (AU) Member States.
1 min |
BioSpectrum Asia Nov 2025
BioSpectrum Asia
How Private Sector is Fueling APAC Vax Demand
As vaccine debates resurface in global politics, most recently fuelled by renewed anti-vaccine rhetoric from the US President Donald Trump, attention is once again turning to the critical role vaccines play in safeguarding public health. Across the Asia-Pacific region, vaccines are evolving from a purely public health tool into a broader healthcare priority with growing private sector participation. Private-sector vaccine sales now account for an estimated 15-35 per cent of total revenue. According to Frost & Sullivan, private-market shares vary widely from around 20 per cent in China and 25-30 per cent in India to as high as 35-40 per cent in parts of Southeast Asia. Strengthened by post-pandemic health awareness, expanding middle-class purchasing power, and new manufacturer strategies, Asia's private vaccine market is becoming an increasingly important force shaping growth, innovation, and access across the region. Let's explore further.
9 min |
BioSpectrum Asia Nov 2025
BioSpectrum Asia
WHO upgrades public health intelligence system
The World Health Organization (WHO), in collaboration with key partners and supporters, has launched version 2.0 of the Epidemic Intelligence from Open Sources (EIOS) system, used globally for the early detection of public health threats.
1 min |
BioSpectrum Asia Nov 2025
BioSpectrum Asia
Vietnam Rises as a Key Pharmerging Market
Vietnam is emerging as one of Asia's most promising pharmaceutical and biotechnology markets. As the government advances its national pharma strategy and regional collaborations deepen, the country is positioning itself as a future hub for biotech in Southeast Asia. We look at how the key trends are shaping Vietnam's pharma and biotech sectors from regulatory reforms and investment flows to the rise of local innovators.
4 min |
BioSpectrum Asia Nov 2025
BioSpectrum Asia
Vision Science and Technology invests HK$5 M for myopia and presbyopia management
The Hong Kong Polytechnic University (PolyU) has received funding support of HK$5 million from Vision Science and Technology (VST), a PolyU startup specialised in pioneering myopia control technologies.
1 min |
BioSpectrum Asia Nov 2025
BioSpectrum Asia
Shimadzu introduces new software to detect impurities
Shimadzu Corporation has released LabSolutions Detect, a software with AI functionality to support anomaly detection for Liquid Chromatographs (LC).
1 min |
BioSpectrum Asia Nov 2025
BioSpectrum Asia
Texas Medical Center unveils BioBridge with South Korea
A new collaboration between Texas Medical Center, the world's largest innovation hub, and the Osong Medical Innovation Foundation (KBIOHealth), South Korea's leading national medical initiative, is set to accelerate the market entry and commercialisation of Korean startups in the United States through the TMC | Republic of Korea BioBridge.
1 min |
BioSpectrum Asia Nov 2025
BioSpectrum Asia
Australia invests $13.6 M to strengthen its status in world-class clinical trials
The Australian Government is investing $13.6 million to progress key national health and medical research reforms; improve earlier access to emerging treatments, strengthen Australia's clinical trials and deliver better health outcomes for Australians.
1 min |
BioSpectrum Asia Nov 2025
BioSpectrum Asia
Alpha Fusion builds joint initiative with Kobe City Medical Center General Hospital
Japan's startup Alpha Fusion Inc. has announced a joint initiative with the Kobe City Medical Center General Hospital (KCGH) to establish a domestic supply system for investigational drugs utilising Astatine-211 (At211).
1 min |
BioSpectrum Asia Nov 2025
BioSpectrum Asia
UAE strengthens medical preparedness in emergencies and crises
The Ministry of Health and Prevention (MOHAP), in the United Arab Emirates (UAE), has signed several agreements with many private hospitals from across the UAE to enhance cooperation in areas of preparedness and response to emergencies and reinforce integration between public and private sectors.
1 min |
BioSpectrum Asia Nov 2025
BioSpectrum Asia
Private Market Vaccines Drive Growth and Strategy Shifts Across China
The vaccine landscape in Asia-Pacific is evolving rapidly as private or self-paid vaccination emerges as a key growth driver. In China in particular, vaccines such as human papillomavirus (HPV) and pneumococcal conjugate vaccine (PCV) dominate the self-paid segment, reflecting both rising consumer demand and growing awareness of preventive health.
2 min |
BioSpectrum Asia Nov 2025
BioSpectrum Asia
Japan develops action plan to use AI in operations
The Pharmaceuticals and Medical Devices Agency (PMDA), Japan's regulatory authority, has developed an Action Plan for the use of AI in Operations.
1 min |
BioSpectrum Asia Nov 2025
BioSpectrum Asia
Starpharma announces collaboration worth $564 M with Genentech for cancer therapies
Starpharma, an Australian biotechnology company, has announced the signing of a collaboration and license agreement with Genentech, a member of the Roche Group, to develop potential cancer therapies that leverage Starpharma's proprietary DEP drug delivery technology.
1 min |
BioSpectrum Asia Nov 2025
BioSpectrum Asia
World Bank approves new financing to enhance Nigeria's health security
The World Bank has approved two projects to support Nigeria's efforts in expanding digital infrastructure and strengthening health security systems.
1 min |
BioSpectrum Asia Nov 2025
BioSpectrum Asia
Boehringer Ingelheim signs $991 M deal with Korea's Aimed Bio for cancer ADC portfolio
Germany's Boehringer Ingelheim and Korean biotech startup AimedBio have announced a global collaboration and licensing agreement to develop a novel antibody-drug conjugate (ADC) therapy for a broad range of cancers.
1 min |
BioSpectrum Asia Nov 2025
BioSpectrum Asia
Mind Over Matter: Decoding China's BCI Push
Once popularised by Elon Musk's Neuralink, brain-computer interface (BCI) technology is now drawing major interest in China. We now look at how the country is stepping up research and investment to advance its own BCI ecosystem.
6 min |
BioSpectrum Asia Nov 2025
BioSpectrum Asia
South Korea establishes first comprehensive plan for organ and tissue donation
The Ministry of Health and Welfare (MOHW), South Korea government, has finalised the First Comprehensive Plan for Organ Donation and Transplantation (2026-2030) following a review by the Organ Transplant Ethics Committee.
1 min |